Scientists identify possible trigger for type 1 diabetes – UPI.com
AURORA, Colo., Feb. 12 (UPI) — Scientists have identified a hybrid insulin peptide as the possible trigger for the autoimmune response causing type 1 diabetes, according to a new study with mice.
University of Colorado researchers made the finding while working to understand why immune cells attack the body’s own tissues, finding a mutation causing the formation of the hybrid peptides.
Type 1 diabetes is an inherited autoimmune disorder, which involves insulin-producing beta cells in the pancreas to be destroyed by immune cells.
“Our lab studies the type of T cell known as a CD4 T cell,” said Dr. Kathryn Haskins, a professor of immunology and microbiology at the University of Colorado School of Medicine, in a press release. “We have focused on autoreactive CD4 T cells using a mouse model of autoimmune diabetes. We have been especially interested in identifying the antigens that activate these T cells.”
The researchers first worked with mice, using mass spectrometry, to find the peptide targets of CD4 T cells in type 1 diabetes.
They found a new class of antigen present in beta cells consisting of insulin fragments fused to peptides of other proteins, which leads to the generation of hybrid insulin peptides not encoded in an individual’s genome. The mutation no longer matching the proper gene is then identified as a foreign body, causing the autoimmune response.
Researchers write in the study, published in the journal Science, that similar hybrid peptides were found in T cells isolated from the pancreatic islets of two people with type 1 diabetes as well. This, they said, suggests future research into their possible role in driving the disease.
Related UPI Stories
Latest Headlines
PAMPLONA, Spain, Feb. 12 (UPI) — A researcher in Spain has used inertial sensors during a “chair test” to easily evaluate frailty in older people based on the physical demands of standing up.
NEW ORLEANS, Feb. 12 (UPI) — Patients whose nerves were frozen before knee surgery had shorter hospital stays, fewer symptoms, and required fewer opioid painkillers, according to a study.
BOSTON, Feb. 12 (UPI) — A two-drug combination affecting the opioid system may help people with treatment-resistant depression, researchers in Boston report in a new study.
MADRID, Feb. 11 (UPI) — A combination of the drugs dasatinib and demcizumab stopped the growth of an aggressive form of lung cancer in mice and human tumor samples in a new study.
SOBORG, Denmark, Feb. 11 (UPI) — Maternal obesity does not have nearly as large an effect on the infant microbiome as the transition from breastfeeding to food, according to a study in Finland.
LONDON, Feb. 11 (UPI) — Blocking a protein related to stress can relieve chronic pain, researchers found in a recent study with mice.
LIVERPOOL, England, Feb. 11 (UPI) — A device, Odoreader, successfully “smelled” prostate cancer in men during a trial using a gas chromatography sensor system, researchers reported.
WASHINGTON, D.C., Feb. 11 — Vice President Joe Biden is using his final 11 months in office to lay the groundwork for his next big ambition — to double the pace of cancer research.
BOSTON, Feb. 11 (UPI) — The risk for developing dementia has dropped by about 20 percent per decade since the 1970s, a new study finds, despite longtime predictions for increases.
NASHVILLE, Feb. 10 (UPI) — Prostate cancer survivors are likely to die of something other than cancer because of early detection and better treatment, according to a recent study.